| (USD) | Sep 2023 | Q/Q |
|---|---|---|
| Revenue | 699K | -5% |
| Operating Income | -3.6MM | -31% |
| Operating Expenses | 4.3MM | - |
| Net Income | -4.1MM | -30% |
| R&D | 1.2MM | -13% |
| G&A | 2MM | -16% |
| Marketing | 336.2K | -71% |
| Amortization | 187.3K | -0% |
| Interest Expense | 396.8K | -42% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
David Lazar invests $3 million in Preferred StockNew OpGen Board of Directors appointedDavid Lazar will take over as CEO of OpGenOpGen settles outstanding liabilities with EIB ROCKVILLE, Md., March 25, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), announced today that the Company entered into a securities purchase agreement with David E. Lazar, an experienced private investor, pursuant to which he will acquire 3,000,000 shares of Series E Convertible Preferred St
Total revenue for the first nine months of 2023 was approximately $2.35 million compared to approximately $1.89 million in the first nine months of 2022Implemented certain cash management initiatives, including restructuring U.S. operations by reducing headcount during the third quarter of 2023Signed preferred stock purchase agreement with a potential strategic investor in October 2023Entered into a warrant inducement agreement with an institutional investor in October 2023Subsidiaries Curetis G
ROCKVILLE, Md., Oct. 12, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that it has entered into an agreement with an institutional investor that is an existing holder of warrants to purchase common shares of the Company for cash (the “Existing Warrants”), wherein the investor agreed to exercise the Existing Warrants to pur
Bloomberg Apple and Suppliers Face Unanticipated Sales Slump Despite New Launches In a surprising turn of events, Apple Inc (NASDAQ: AAPL) and its key suppliers in Taiwan are facing a significant sales slump despite the recent launch of the new iPhone and various Android devices. Taiwan Semiconductor Manufacturing Co (NYSE: TSM), the leading contract chipmaker, experienced a 13.4% sales drop, a figure that, while concerning, is better than initially feared. Arm's Chinese Fortunes in Jeopardy? In
OpGen, Inc. (NASDAQ:OPGN) Q2 2023 Earnings Call Transcript August 10, 2023 OpGen, Inc. misses on earnings expectations. Reported EPS is $-0.93 EPS, expectations were $-0.71. Operator: Welcome to OpGen’s Second Quarter 2023 Earnings Call and Business Update. Before we turn the call over to OpGen management, please note that any forward-looking statements made during this […]
Q2 2023 OpGen Inc Earnings Call
Total revenue for the first half of 2023 was approximately $1.65 million, an increase of approximately 15% compared to approximately $1.44 million in the first half of 2022Signed FIND R&D collaboration contract extensionEntered distribution agreement with Fisher Healthcare for the distribution of the Unyvero A50 platform in the U.S.Management conference call is scheduled for August 10, 2023, at 4:30 p.m. ET ROCKVILLE, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “
Single nucleotide polymorphism (SNP) analysis module and interpretation of plasmids now availableAdded reporting customized for the needs of hospital epidemiologists Signed first large commercial contract with U.S. healthcare network using the new features ROCKVILLE, Md., Aug. 07, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, and OpGen subsidiary, Ares Gen
Signed contract amendment is part of an overall strategic priority collaboration in the fight against AMR using Unyvero A30 platform in LMICsNext phase to cover full AMR assay and cartridge development, analytical testing and software developmentRelated payments of up to approximately $0.6 million will bring total collaboration commitment to date to approximately $1.5 million ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medic
ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter 2023 financial results after the close of the U.S. financial markets on Thursday, August 10th 2023. OpGen’s management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide an update on business activities. Conference C